Abdulzahra Hussain1, Hind Mahmood, Shamsi El-Hasani. 1. Minimal Access and Bariatric Surgery Unit, General Surgery Department, Princess Royal University Hospital, Orpington, Greater London, UK. azahrahussain@yahoo.com
Abstract
BACKGROUND: The surgical treatment of diabetes had witnessed progressive development and success since the first case of pancreatic transplantation. Although this was a great step, wide clinical application was limited by several factors. Bariatric surgery such as gastric bypass is emerging as a promising option in obese patients with type 2 diabetes. The aim of this article is to explore the current application of gastric bypass in patients with type 2 diabetes and the theoretical bases of gastric bypass as a treatment option for type 1 diabetes. METHODS: We performed a MEDLINE search for articles published from August 1955 to December 2008 using the words "surgical treatment of diabetes," "etiology of diabetes" and "gastric bypass." RESULTS: We identified 3215 studies and selected 72 relevant papers for review. Surgical treatment of diabetes is evolving from complex pancreatic and islets transplantation surgery for type 1 diabetes with critical postoperative outcome and follow-up to a metabolic surgery, including gastric bypass. Gastric bypass (no immune suppression or graft rejection) has proven to be highly effective treatment for obese patients and nonobese animals with type 2 diabetes. There are certain shared criteria between types 1 and 2 diabetes, making a selected spectrum of the disease a potential target for metabolic surgery to improve or cure diabetes. CONCLUSION: Roux-en-Y gastric bypass is a promising option for lifelong treatment of type 2 diabetes. It has the potential to improve or cure a selected spectrum of type 1 diabetes when performed early in the disease. Further animal model studies or randomized controlled trials are needed to support our conclusion.
BACKGROUND: The surgical treatment of diabetes had witnessed progressive development and success since the first case of pancreatic transplantation. Although this was a great step, wide clinical application was limited by several factors. Bariatric surgery such as gastric bypass is emerging as a promising option in obesepatients with type 2 diabetes. The aim of this article is to explore the current application of gastric bypass in patients with type 2 diabetes and the theoretical bases of gastric bypass as a treatment option for type 1 diabetes. METHODS: We performed a MEDLINE search for articles published from August 1955 to December 2008 using the words "surgical treatment of diabetes," "etiology of diabetes" and "gastric bypass." RESULTS: We identified 3215 studies and selected 72 relevant papers for review. Surgical treatment of diabetes is evolving from complex pancreatic and islets transplantation surgery for type 1 diabetes with critical postoperative outcome and follow-up to a metabolic surgery, including gastric bypass. Gastric bypass (no immune suppression or graft rejection) has proven to be highly effective treatment for obesepatients and nonobese animals with type 2 diabetes. There are certain shared criteria between types 1 and 2 diabetes, making a selected spectrum of the disease a potential target for metabolic surgery to improve or cure diabetes. CONCLUSION: Roux-en-Y gastric bypass is a promising option for lifelong treatment of type 2 diabetes. It has the potential to improve or cure a selected spectrum of type 1 diabetes when performed early in the disease. Further animal model studies or randomized controlled trials are needed to support our conclusion.
Authors: Leszek Czupryniak; Janusz Strzelczyk; Katarzyna Cypryk; Maciej Pawlowski; Dariusz Szymanski; Andrzej Lewinski; Jerzy Loba Journal: Diabetes Care Date: 2004-10 Impact factor: 19.112
Authors: W J Pories; K G MacDonald; E G Flickinger; G L Dohm; M K Sinha; H A Barakat; H J May; P Khazanie; M S Swanson; E Morgan Journal: Ann Surg Date: 1992-06 Impact factor: 12.969
Authors: A M James Shapiro; Camillo Ricordi; Bernhard J Hering; Hugh Auchincloss; Robert Lindblad; R Paul Robertson; Antonio Secchi; Mathias D Brendel; Thierry Berney; Daniel C Brennan; Enrico Cagliero; Rodolfo Alejandro; Edmond A Ryan; Barbara DiMercurio; Philippe Morel; Kenneth S Polonsky; Jo-Anna Reems; Reinhard G Bretzel; Federico Bertuzzi; Tatiana Froud; Raja Kandaswamy; David E R Sutherland; George Eisenbarth; Miriam Segal; Jutta Preiksaitis; Gregory S Korbutt; Franca B Barton; Lisa Viviano; Vicki Seyfert-Margolis; Jeffrey Bluestone; Jonathan R T Lakey Journal: N Engl J Med Date: 2006-09-28 Impact factor: 91.245
Authors: Camila Puzzi de Carvalho; Daniela Miguel Marin; Aglécio Luiz de Souza; José Carlos Pareja; Elintom Adami Chaim; Silvia de Barros Mazon; Conceição Aparecida da Silva; Bruno Geloneze; Elza Muscelli; Sarah Monte Alegre Journal: Obes Surg Date: 2008-09-25 Impact factor: 4.129
Authors: Dominique Delmeire; Daisy Flamez; Karen Moens; Simon A Hinke; Chris Van Schravendijk; Daniel Pipeleers; Frans Schuit Journal: Biochem Pharmacol Date: 2004-07-01 Impact factor: 5.858
Authors: Camila M Yamaguchi; Joel Faintuch; Silvia Y Hayashi; Jacob J Faintuch; Ivan Cecconello Journal: Surg Endosc Date: 2012-04-27 Impact factor: 4.584
Authors: Kamal K Mahawar; Nimantha De Alwis; William R J Carr; Neil Jennings; Norbert Schroeder; Peter K Small Journal: Obes Surg Date: 2016-01 Impact factor: 4.129
Authors: John P Kirwan; Ali Aminian; Sangeeta R Kashyap; Bartolome Burguera; Stacy A Brethauer; Philip R Schauer Journal: Diabetes Care Date: 2016-06 Impact factor: 19.112